Linganisha mbinu

	Jaribio la Kifashio la Kufungwa kwa Kiasi Kimoja	Jaribio la Kisayansi la Kidhibiti cha Machafuko lenye Kufunikwa kwa Upande Mmoja
Nyanja	Muundo wa Majaribio	Muundo wa Majaribio
Familia	Process / pipeline	Process / pipeline
Mwaka wa asili	1940s–1950s (fractional factorial foundations); blinding conventions formalised through 1960s–1980s	1948 (formalized); single-blind variant established in mid-20th century clinical trial methodology
Mwanzilishi	Fractional factorial theory: R. L. Plackett & J. P. Burman (1946); single-blinding practice codified in clinical trial methodology (20th century)	Bradford Hill and colleagues (MRC streptomycin trial, 1948); blinding conventions codified in CONSORT guidelines
Aina	Controlled experimental design	Experimental design — blinded randomized trial
Chanzo asilia	Box, G. E. P., Hunter, J. S., & Hunter, W. G. (2005). Statistics for Experimenters: Design, Innovation, and Discovery (2nd ed.). Wiley-Interscience. ISBN: 978-0471718130	Schulz, K. F., Altman, D. G., Moher, D., & CONSORT Group. (2010). CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ, 340, c332.
Majina mbadala	single-masked fractional factorial, single-blind FFD, partially blinded fractional factorial, single-blind 2^(k-p) design	single-masked RCT, single-blind RCT, single-blind trial, SB-RCT
Zinazohusiana	5	5
Muhtasari	A single-blind fractional factorial experiment studies multiple factors simultaneously by testing only a strategically chosen subset — a fraction — of all possible factor-level combinations, while keeping participants unaware of which treatment condition they receive. This design yields substantial information about main effects and selected interactions at a fraction of the cost of a full factorial experiment, with single-blinding reducing participant-side response bias.	A single-blind randomized controlled trial (SB-RCT) is a rigorous experimental design in which participants are randomly assigned to treatment or control conditions while remaining unaware of which condition they have received. Investigators, outcome assessors, and data analysts are not blinded. By masking participants, the design eliminates placebo and nocebo response biases on the participant side, while preserving investigator flexibility to administer and monitor the intervention.